The Enterprise Value as of November 2024 (TTM) for GlycoMimetics, Inc. (GLYC) is 268.17M

According to GlycoMimetics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 268.17M. This represents a change of 101.60% compared to the average of 133.02M of the last 4 quarters.

GlycoMimetics, Inc. (GLYC) Historical Enterprise Value (quarterly & annually)

How has GLYC Enterprise Value performed in the past?

The mean historical Enterprise Value of GlycoMimetics, Inc. over the last ten years is 109.60M. The current 268.17M Enterprise Value has changed 24.37% with respect to the historical average. Over the past ten years (40 quarters), GLYC's Enterprise Value was at its highest in in the September 2023 quarter at 1.06B. The Enterprise Value was at its lowest in in the March 2020 quarter at -52040144.80.

GlycoMimetics, Inc. (GLYC) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of GlycoMimetics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

GlycoMimetics, Inc. (GLYC) Average Enterprise Value

How has GLYC Enterprise Value performed in the past?

The current Enterprise Value of GlycoMimetics, Inc. (GLYC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

GlycoMimetics, Inc. (GLYC) Enterprise Value vs. Peers

How is GLYC’s Enterprise Value compared to its peers?

GlycoMimetics, Inc.’s Enterprise Value is less than Mineralys Therapeutics, Inc. (0), less than Foghorn Therapeutics Inc. (523.81M), less than Inventiva S.A. (417.24M), greater than Dyne Therapeutics, Inc. (228.20M), less than aTyr Pharma, Inc. (2.51B), greater than Trevi Therapeutics, Inc. (138.44M), greater than Cue Biopharma, Inc. (208.74M), greater than AN2 Therapeutics, Inc. (41.71M), greater than BioAtla, Inc. (6.48M), greater than Assembly Biosciences, Inc. (20.64M), greater than Spero Therapeutics, Inc. (68.59M), greater than Achilles Therapeutics plc (-8426888.00), greater than Instil Bio, Inc. (-38865958.00), greater than Neoleukin Therapeutics, Inc. (165.40M), greater than null (-6333315.00),

Build a custom stock screener for GlycoMimetics, Inc. (GLYC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GlycoMimetics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

GlycoMimetics, Inc. (GLYC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like GlycoMimetics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.